Penumbra, Inc. · NYSE:PEN
Penumbra — Merger or Acquisition (January 2026)
11 slides from Penumbra's merger presentation, Jan 15, 2026
Slide 1: Boston Scientific Announces Agreement to Acquire Penumbra, Inc.
Boston Scientific Advancing science for life TM Boston Scientific Announces Agreement to Acquire Penumbra, Inc. January 15, 2026
Slide 2: Safe harbor for forward-looking statements
Boston Scientific Advancing science for life TM Safe harbor for forward-looking statements Certain statements that we may make from time to time, including statements contained in this presentation and information incorporated by reference herein, constitute forward-looking statements within the mea
Slide 3: Important Information and Where to Find It
Boston Scientific Advancing science for life TM Important Information and Where to Find It In connection with the proposed transaction, Boston Scientific will file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 that will include a proxy statement/prospec
Slide 4: Today's Presenters
Boston Scientific Advancing science for life TM Today's Presenters Boston Scientific Penumbra MIKE MAHONEY Chairman & Chief Executive Officer JONATHAN MONSON Executive Vice President & Chief Financial Officer ADAM ELSESSER Chairman & Chief Executive Officer 4
Slide 5: Our purpose: Advancing science for life
Boston Scientific Advancing science for life TM Our purpose Advancing science for life Caring Meaningful innovation High performance Global collaboration Diversity Winning spirit 5
Slide 6: BSX + PEN: Strong strategic and financial fit
Boston Scientific Advancing science for life TM BSX + PEN: Strong strategic and financial fit Announced definitive agreement to acquire Penumbra, valued at $374 per share Entry into new, key segments with a WAMGR accretive to BSX Mechanical thrombectomy, embolization and neurovascular are large, und
Slide 7: Penumbra, Inc. Overview
Boston Scientific Advancing science for life TM Penumbra, Inc. Overview A leader in vascular solutions focused on developing innovative technologies Headquartered in Alameda, CA Products Manufactured in California Penumbra ~4,500 Employees Product Available in 100+ Markets Financials Q4 and FY 2025
Slide 8: Expanding Into Significant Untapped New Segments
Boston Scientific Advancing science for life TM Expanding Into Significant Untapped New Segments Thrombectomy Total Annual U.S. Opportunity 1,250,000+ Arterial Patients 259K PE Patients 157K Stroke Patients 200K Venous / DVT Patients 351K Coronary Patients 289K Stroke Middle Meningeal Artery Emboliz
Slide 9: Penumbra Portfolio and Pipeline
Boston Scientific Advancing science for life TM Penumbra Portfolio and Pipeline WAMGR of 11% in high-growth adjacent areas Embolization & Access Mechanical Thrombectomy Peripheral Neurovascular ~HSD growth opportunity Key Products Ruby Coil POD, Packing Coil ~Mid-teens growth opportunity Key Product
Slide 10: Entering a New Phase of Innovation-Fueled Growth
Boston Scientific Advancing science for life TM Entering a New Phase of Innovation-Fueled Growth PE / DVT / ALI Computer Assisted Vacuum Thrombectomy (CAVT) for Acute Intermediate-High Risk Pulmonary Embolism (PE) & Acute Limb Ischemia (ALI) Indigo SystemTM + Lightning Flash / Lightning Bolt MMA Mid
Slide 11: Transaction Details
Boston Scientific Advancing science for life TM Transaction Details Expect to complete the transaction in 2026 Transaction Structure Transaction consideration reflects a total equity value of $15B to be funded in approx. $11B in cash and approx. $4B in Boston Scientific stock, resulting in a 73% cas